You are on page 1of 6

05/26/2015 3:08:46 PM

TO:

FROM: LABCORP LCLS BULK

TO:

4 4 3 7 1 6 0 4 1 9

LABCORP

Damanhuri Alkaitis, M.D.

'

/ V

Page

1

of

6

LabCorp

Laboratory Corporation o lT n irle i|

Specimen Number

134-348-0382-0

c r n M

T ’T'P Pad cot First Name

ROBERT

Patient ID

Patient List Name

LabCorp Raritan 69 First Avenue

Cootrol Number

Patient Middle Nime

Account Number

19769532

Accnunt Phone Number

443-716-0420

Account AdcIfTSl

Patient SS#

Age (Y/M/D)

22/11/23

Patient Phone

443-875-4733

Date qJ Birth

05/21/92

Sea

M

Total Volume

Fasting

122 DEFENSE HWY #222 ANNAPOLIS MD 21401

Route

BR

4254 KINGS RD EDGEWATER MD

Patient Address

21037

Date aod Time Collected

05/14/15 00;00

Date Eoteted

05/14/15

Date aod Time Reported

05/26/15

1 5 : 0BET

Physician Name

A L K A IT IS

,

D

Additional Information

UPIN: A60751

NPI

1 5 6 8 4 5 1 3 7 5

Physician ID

Tests Otdered

IFE and PE, Serum; Panel 083824; Anticardiolip Ab,

XgA/G/M, Qn; GH1 Antibody IgG, XgM;

Sjogren's Ab, Anti-SS-A/-ss-B;

a n a w/Reflex; Methylmalonic Acid, Serum; Rheumatoid Arthritis

Factor; Vitamin D, 25-Hydroxy; Cortisol; Anti-dsDNA Antibodies; t-Transglutaminase (tTG) IgA; t-Transglutaminase (tTG) IgG; VGCC Antibody; Creatinine, Serum; ALT (SGPT); RPR; Sedimentation Rate-Westergren; C-Reactive Protein, Quant; Thyroid Peroxidase (TPO) Ab; Creatine Kina3e,Total,Serum; Aldolase; Ambiguous Te3t Order _____________________________________________

|

T ESTS

RESULT

T LAG

IFE and PE, serum Immunoglobulin G,

Qn, Serum

619

LOW

 

Immunoglobulin

A,

Qn, Serum

166

Immunoglobulin

M,

Qn, Serum

14

LOW

Protein, Total, Serum

 

6.4

Albumin

4.1

Alpha-l-Globulin

0.2

Alpha-2-Globulin

 

0.6

Beta Globulin

1.0

Gamma Globulin

0.5

M-Spike

Not observed

 

Globulin, Total

2.3

A/G Ratio

1 •8

Immunofixation Result, Serum An apparent normal immunofixation

 

Please note:

Protein electrophoresis scan will

courier delivery.

Panel 083824

HIV 1/0/2 Abs-ICMA HIV 1/0/2 Abs-index Value

< 1.00

i H

U

K

A

v

a

i u

w

-----------------------

-

-

.

HIV 1/0/2 Abs, Qual

Non Reactive

Anticardiolip Ab, igA/G/M, Qn

 

Anticardiolipin Ab,lgG,Qn

 

<9

UNITS

REFERENCE

INTERVAL

LAB

|

mg/dL

700 - 1600

01

mg/dL

91

- 414

01

mg/dL

40 - 230

01

g/dL

6.0 - 8.5

01

g/dL

3.2 - 5.6

01

g/dL

0.1

- 0.4

01

g/dL

0.4 - 1.2

01

g/dL

0.6 - 1.3

01

g/dL

0.5 - 1.6

01

g/dL

Not Observed

01

g/dL

2.0

- 4.5

0.7 - 2.0

 
 

01

01

via computer, mail, or

 
 

01

 

<1.00

01

to the negative cutoff. Non Reactive

01

GPL U/mL

0-14

01

Negative:

<15

Indeterminate :

15-20

 

Low-Med Positive: >20 - 80

High Positive s

>80

ROBERT

  • 1 SCH M ITT,_________________________________

05/26/15 15:08 ET

FINAL REPORT

This document contains private and confidential health infonnatlon protected by state and federal law. If you have received (his document in error, please call 8 0 0 - 6 3 1 - 5 2 5 0

1 3 4 - - 3 4 8 - 0 3 8 2 - 0

| Seq # 3494

0 2 0 0 4 -1 5 Laboratory Corporation of America ® Holding All Rights Reserve

DOCl Vet: 1.4

05/26/2015 3:08:46 PM

TO:

FROM:LABCORPLCLSBULK

TO: 4437160419

LABCORP

Damanhuri Alkaitis, M.D.

Page 2

ol

6

LabCorp

Laboratory Corporation ol Xa w e jI

SCHMITT, ROBERT

LabCorp Raritan

69 First Avenue Raritan, NJ 08869-1800

Patient Name

Phone: 800-631-5250

Spedmeo Number

134-348-0382-0

Account Number

Pad eat ID

Coctrol Number

Date tod Time Collected

Date

Reported

Sex

M

Age(Y/M/D)

Dale of Birth

1 9 7 6 9 5 3 2

0 5 / 1 4 / 1 5

0 0 : 0 0

0 5 /

2 6 / 1 5

2 2 / 1 1 / 2 3

0 5 / 2 1 / 9 2

TESTS

RESULT

FLAG

UNITS

REFERENCE

INTERVAL

LAB

Anticardiolipin Ab,IgM,Qn

<9

MPL U/rtiL

0 12

-

01

 

Negative:

 

<13

Indeterminate:

13 - 20

 

Low-Med Positive: >20 - 80

High Positive:

 

>8 0

Anticardiolipin Ab,IgA,Qn

<9

APL U/mL

0 11

-

01

Negative:

 

<12

 

Indeterminate:

12 - 20

 

Low-Med Positive: >20 - 80

High Positive:

 

>80

C»il Antibody IgG, IgM

 

Anti-GMl (IgM)*

<1:100

titer

02

Reference Range:

Negative: < 1:100 titer Positive: => 1:100 titer Titers of less than 1:400 may not be clinically significant. We suggest clinical correlation to ascertain the significance of the low titers.

Antibodies against glycolipids (GM1, GDla, GDlb, GQlb, asialo GM1, and sulfatides) are present in patients with Guillain-Barre syndrome (GBS), IgM paraproteinemic neuropathy, and chronic demyelinating polyneuropathy (CIDP). Antibodies to one or more glycolipids are present in 60-70% of patients with GBS. The titers of anti-glycolipid antibodies are higher in acute phase and decrease in association with clinical improvement. Antibodies against GM1 and/or GDlb are frequently present in acute phase GBS. The two antibodies together occur in about 20% of these cases, anti-GMl without anti-GDlb antibodies in about 10% and anti-GDlb without anti-GMl antibodies in about 10% of GBS patients. Antibodies against GQlb of igG isotype are present in 95% of patients with Miller Fisher syndrome (MFS). The titers of these antibodies fluctuates with disease activity. IgM paraproteinemia is often associated with peripheral neuropathies. These antibodies are present in one half of patients with specificity for SGPG, GDlb and other gangliosides. Anti-GMl IgM antibodies are usually associated with motor-dominant or sensorimotor neuropathies. These antibodies are also elevated in diseases other than multifocal neuropathies such as GBS, CIDP and other immunological diseases.

♦This test has been developed and performance parameters have been validated by IMMCO Diagnostics, Inc. This test has not been approved by the U.S. Food and Drug Administration

fSCHMITT, ROBERT

05/26/15 15:08 ET

|

FINAL REPORT

This Uaruincnl contains private and confidential health information protected by state and federal law. If you have received this document in error, please call 8 0 0 - 6 3 1 - 5 2 5 0

1

13 4 - 3 4 8 - 0 3 8 2 - 0

|

Seg tt W.

Page 2 of 5

© 2 0 0 4 -1 5 Laboratory Corporation of America Hold All Rights Resei DOC1 Ver:

05R6/2015 3:08:46 PM

1

FROM: LABCORP LCLS BULK

TO:4437160419

LABCORP

Damanhurl Alkaitis, M.D.

Page 3 of 6

LabCorp

UhotMoty

SCHMITT, t ROBERT

Aecotiot Number 1 9 7 6 9 5 3 2

Patient ID

TESTS

LabCorp Raritan

69 First Avenue Raritan, NJ 08869-1800

Patient Name

Cootrol Number

Date and Time Collected

0 5/ 1 4/ 1 5

0 0 :0 0

RESULT

FLAG

Date Reported

0 5/ 2 6/ 1 5

UNITS

Phnne:

Specimen Number

134-348-0382-0

Sex

Age(Y/M/D)

Date of Birth

M

2 2/ 1 1/ 2 3

0 5/ 2 1/ 9 2

REFERENCE

INTE1 IV AL

LAB

(FDA); however, US FDA approval is not required

for clinical

use. it is not intended that clinical diagnosis and patient

management decisions be made using these results alone.

This test has been validated using serum samples. The

manufacturer has not determined the efficacy of this test when performed on CSF, plasma, joint or pleural fluid specimens. The performance characteristics of this test were t determined by IMMCO Diagnostics Inc.

Anti-GMl (IgG)* Reference Range:

<1:100

titer

Negative: < 1:100 titer Positive: => 1:100 titer

Sjogren's Ab, Anti-SS-A/-SS-B

Sjogren's Anti-SS-A

<0.2

AI

Sjogren's Anti-SS-B

<0.2

AI

ANA w/Reflex

ANA Direct

Negative

Methylmalonic Acid, Serum

337

nmol/L

Rheumatoid Arthritis Factor

RA Latex Turbid.

9.0

IU/mL

Vitamin D, 25-Hydroxy

14.3

Low

ng/mL

Vitamin D deficiency has been defined by tne institute ot

Medicine and an Endocrine Society practice guideline as a

level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D

insufficiency as a level between 21 and 29 ng/mL (2).

  • 1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press.

  • 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine society clinical practice guideline. JCEM. 2011 Jul; 96(7)s1911—30.

Cortisol

| SCHMITT, ROBERT

05/26/15 15:08 ET

4.6

ug/dL

Cortisol AM

Cortisol PM

I

___________

|

1

3

4

- 3

FINAL REPORT

 

02

   

01

0.0 - 0.9 0.0 - 0.9

01

Negative

01

 

0 - 378

 

03

0.0 - 13.9

01

30.0 - 100.0

01

 

■»

 

2.3 -

19.4

01

6.2

 

- 19.4

2.3

- 11.9

4

8

- 0

3

8

2

- 0

I

S e q # 3 4 9 4 ~ (

 

Page 3 of 5

This document contains private and confidential health infonnadon protected by state and federal law. If you have received this document in error, please call 8 0 0 - 6 3 1 - 5 2 5 0

© 2004-15 Laboratory Corporation of America ® Holdings All Rights Reserved DOC l Ver: 1.49

05/26/2015 3:08:46 PM

JO:

FROM: LABCORP LCLS BULK

TO: 4437160419

Damanhuri Alkaitis, M.D.

LABCORP

Page 4

LabCprp

SCHMITT, ROBERT

Account Number

1 9 7 6 9 5 3 2

Patient ID

TESTS

Anti-dsDNA Antibodies

Anti-DNA (DS) Ab Qn

t-Transglutaminase (tTG) IgA

LabCorp Raritan 69 First Avenue Raritan. NJ 0SS69-1800

Pan an Name

Control Number

Date

and Time Collected

C 5 / 1 4 / 1 5

0 0 : 0

0

RES tJLT

h a g

Phone: 800-631-52*

 

Sped men Number

1 3 4 - 3 4 8 - 0 3 8 2 -

Date Reported

Sea

Age(Y/M/D)

Datee

0 5 /

2 6 / 1 5

M

2 2 / 1 1 / 2 3

0 5/ 2

UNITS

REFERENCE

INTERVAL

<2

IU/mL

0

-

9

Negative

<5

Equivocal

5

-

9

Positive

>9

U/mL

0

-

3

Negative

0

-

3

Weak Positive

4

-

10

Positive

>10

Tissue Transglutaminase (tTG) has been identified

as the endomysial antigen.

Studies have demonstr­

ated that endomysial IgA antibodies have over 99% specificity for gluten sensitive enteropathy.

t-Transglutaminase (tTG) IgG

2

U/mL

0

-

5

 

Negative

0

- 5

Weak Positive

6

- 9

Positive

>9

VGCC Antibody

Negative

Negative

Results for this test are for research purposes only by the assay's manufacturer. The performance characteristics of this product have

not been established.

Results should not be used as a diagnostic

procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.

Creatinine, Serum Creatinine, Serum

0.75

Low

eGFR if NonAfricn An

130

eGFR If Africn Am

151

ALT (SGPT)

25

RPR

Non Reactive

 

Sedimentation Rate-Westergren

 

2

C-Reactive Protein, Quant

0.8

Thyroid Peroxidase (TPO) Ab

316

High

rtig/dL

mL/min/l.73

raL/min/1.73

IU/L

0.76 - 1.27

>59

>59

0-44

Non Reactive

mra/hr

mg/L

IU/mL

0-15

0.0 - 4.9

0-34

I s c h m i t t , Ro b e r t "

05/26/15 15i08 ET

FINAL REPORT

TUi document contains private and confidential health information protected by atate and federal law. If you have received das document in error, please call 8 0 0 - 6 3 1 - 5 2 5 0

| 134-348-0382-0

Sci

Page 4 of

© 2004-15 Laboratory Corporation of America « All Riph1

DOC

05/26/2015 3:08:46 PM

TO:

FROM: LABCORP LCLS BULK

TO: 4437160419

Damanhuri Alkaitis, M.D.

LABCORP

f

LabCorp

Laboratory Corporation of & m *rba| ~~

SCHMITT, ROBERT

Accouat Number

1 9 7 6 9 5 3 2

Patieor ID

TESTS

Creatine Kinase,Total,Serum

Aldolase

Ambiguous Test Order

LabCorp Raritan 69 First Avenue

 

Raritan, N J

0 8 8 6 9 - 1 8 0 0

PabMI Name

Control Number

Date and Time Collected

0 5 / 1 4 / 1 5

0 0 : 0 0

RESULT

FLAG

98

4 . 6

 

Phone: 800-<

Specimen N

134-348-1

Date Reported

Sex

Age(Y/M/Dl

0 5 / 2 6 / 1 5

M

2 2 / 1 1 / 2 3

U N ITS

REFERENCE

 

IN

I2

U/L

2 4

-

2C

U/L

3 . 3

-

1C

Test not performed. The test requested has been discontinued and o:

is no longer available. Please refer to LabCorp*s online Directory

of Services for current test offerings or contact your LabCorp representative for assistance. Test: MATA

  • 01 LabCorp Raritan 69 First Avenue, Raritan, NJ 08869-1800

RN

Dir: Araceli

B Reyes, HD

  • 02 Iiranco Diagnostic Inc

GK

Dir: Thomas Shanahan,

PhD

640 Ellicott Street, Buffalo, NY 14203-1245

  • 03 LabCorp Burlington

BN

Dir: William F Hancock, HD

1447 York Court, Burlington, NC 27215-3361 For Inquiries, the physician may contact Branchs 800-631-5250 Lab: 800-631-5250

1 SCHMITT, ROBERT

05/26/15

15:08

ET

FINAL REPORT

134- 348-0382 Pa

05/26/2015 3:08:46 PM

TO:

FROM: LABCORP LCLS BULK

70:4437160419

Damanhuri Alkaitls, M.D.

Laboratory Corporation o f America

Special Chemistry Department Raritan, New Jersey

Serum Imtnunofixation

LABCORP

Accession No:

  • 134348038209 Account No./Name:

19769532-Damanhuri Alkai

Total Protein: 6.4 ALKAITIS D D ID : Patient Name: SCHMITT,ROBERT Account Address 1: Patient Id:
Total Protein:
6.4
ALKAITIS D
D ID :
Patient Name:
SCHMITT,ROBERT
Account Address 1:
Patient Id:
Account Address 2:
Birthdate:
21-MAY-1992
Account Address 3:
122 DEFENSE HWY <222
ANNAPOLIS, MD 21401
SPIFE SPE Split Beta Sample 56 05-15-2015 1 3 i 1 6 i 44«55
SPIFE SPE Split Beta
Sample 56
05-15-2015
1 3 i 1 6 i 44«55

Fraction

%

g/dL

g/dL Range

Albumin

63.3

4.1

3.2

5.6

Alpha 1

3.0

0.2

0.1

0.4

Alpha 2

9.0

0.6

0.4

1.2

Beta

16.3

1.0

0.6

1.3

Gamma

8.4

0.5

0.5

1.6

Total

6.4

6.0

8.5

Immunofixation Interpretation:

An apparent normal immunofixation pattern